Skip to content
sellWeak cluster of 4

Edward M. Kaye MD sold $65k of STOK

CEO at Stoke Therapeutics, Inc.. 2,136 shares at an average of $30.22, traded Dec 2, 2025, filed Dec 3, 2025.

Warning score
23
Value
$65k
2,136 shares
Holdings after
51,305
-4% from before
From 52-week low
+405%
low $5.90, close $29.81
From 52-week high
-16%
high $35.60, as of Dec 2, 2025

Score components

  • Role
    Director
    +15
  • Trade size
    $65k at market
    +8
  • Share of holdings sold
    Sold 4.0% of holdings
    0
  • Cluster
    4 insiders selling within 14 days
    +15
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

STOKOct 9, 2026 · close 24.74
Since filing Dec 3, 2025: -20.1%SPY +15.1% · excess -35.2%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001522780-25-000008, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 1, 2024MOption exercise
Common Stock
+4,317$0.00$053,441Dec 3, 2025
Dec 2, 2025SOpen-market sale
Common Stock
-661$29.56$20k52,780Dec 3, 2025
Dec 2, 2025SOpen-market sale
Common Stock
-405$30.14$12k52,375Dec 3, 2025
Dec 3, 2025SOpen-market sale
Common Stock
-419$30.34$13k51,956Dec 3, 2025
Dec 3, 2025SOpen-market sale
Common Stock
-651$30.85$20k51,305Dec 3, 2025
Dec 1, 2025MOption exercise
Restricted Stock Unitsderivative
-4,317$0.00$00Dec 3, 2025

Related signals

Other insiders at Stoke Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
3Weak
STOKsell 210b5-1
Stoke Therapeutics, Inc.
Jonathan Allan
GENERAL COUNSEL & CORP SEC
$17k
627 shares
-3%
8Weak
STOKsell 210b5-1
Stoke Therapeutics, Inc.
Barry Ticho
CHIEF MEDICAL OFFICER
$27k
1,051 shares
-5%
11Weak
STOKsell10b5-1
Stoke Therapeutics, Inc.
Barry Ticho
CHIEF MEDICAL OFFICER
$170k
5,545 shares
-22%
27Weak
STOKsell 210b5-1
Stoke Therapeutics, Inc.
Jonathan Allan
GENERAL COUNSEL & CORP SEC
$313k
9,293 shares
-32%
42Moderate
STOKsell 2
Stoke Therapeutics, Inc.
Jonathan Allan
GENERAL COUNSEL & CORP SEC
$286k
8,895 shares
-24%
43Moderate
STOKsell 2
Stoke Therapeutics, Inc.
Jason Hoitt
Chief Patient Officer
$119k
3,712 shares
-27%
31Weak
STOKsell 410b5-1
Stoke Therapeutics, Inc.
Jonathan Allan
GENERAL COUNSEL & CORP SEC
$128k
3,978 shares
-25%
32Weak
STOKsell 410b5-1
Stoke Therapeutics, Inc.
Edward M. Kaye MD
CEO
$433k
13,430 shares
-21%
19Weak
STOKsell 410b5-1
Stoke Therapeutics, Inc.
Jonathan Allan
GENERAL COUNSEL & CORP SEC
$306k
9,803 shares
-38%
17Weak
STOKsell 410b5-1
Stoke Therapeutics, Inc.
Edward M. Kaye MD
CEO
$467k
15,001 shares
-19%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Edward M. Kaye MD sold $65k of STOK | InsiderTell